ImmuDyne Announces Record Third Quarter 2017 Revenue
October 16 2017 - 12:38PM
ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader
in the development and online marketing of OTC health and wellness
products addressing large unmet needs, today announces its
unaudited financial results for the third fiscal quarter of
2017.
ImmuDyne and its online direct-response marketing subsidiary,
ImmuDyne PR, report that they collectively achieved record gross
revenue of $2.077M in the third quarter. As was stated previously
in our September 20, 2017 press release, the Company anticipates
continued quarterly revenue growth from our existing brands and
from new brands launching over the next 2 quarters. New
product launch expenses will be internally financed by the
company’s increasing cashflow Cash on hand was
approximately $600,000, as of September 30, 2017.
“We believe this quarter’s performance represents a major
inflection point for ImmuDyne,” stated Mark McLaughlin, CEO of
ImmuDyne. “We continue to be extremely happy with the launch of
Shapiro MD. We are profitable, and well prepared for significant
growth over the next several quarters.”
About Shapiro MD™
The Shapiro MD product line is the result of 15 years of
research and development by thought-leading dermatologists Dr.
Steven Shapiro and Dr. Michael Borenstein. It is protected by
two U.S. patents and is the only product in the hair loss vertical
that contains what we believe are the 3 most powerful,
naturally-occurring dihydrotestosterone (DHT) blocking
ingredients. DHT is widely believed to be the main culprit of
balding/hair-loss. For more information on Shapiro MD or to
purchase the product, please visit www.shapiromd.com.
About ImmuDyne
ImmuDyne, Inc. (the "Company") is a health and wellness company
that develops, manufactures, and markets innovative consumer
products. ImmuDyne manufactures and markets a proprietary and
patent protected Yeast Beta Glucan that has been shown in thousands
of clinical studies to support and regulate the human immune
system. It has broad applications in skincare and as an
immune support supplement. ImmuDyne PR, a majority owned
subsidiary of ImmuDyne, Inc., is the digital marketing arm of
ImmuDyne and is currently focused on marketing products for thicker
and fuller hair (Shapiro MD) and a skincare line containing
ImmuDyne’s proprietary Yeast Beta Glucan ingredient (Inate
MD). All of ImmuDyne's intellectual property is protected by
patents and/or trade secrets. Additional information can be found
on the web at www.ImmuDyne.com
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe
Harbor Act Disclaimer: Forward looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Certain statements in
this press release, including projections with respect to
ImmuDyne's results of operations, may contain words such as
"anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other
similar language and are considered forward-looking statements.
These statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
The preliminary, unaudited information provided above is based
on the Company’s current estimate of results from operations for
the third quarter and its cash at September 30, 2017, and
remains subject to change based on the Company’s closing
procedures, including the subsequent occurrence or identification
of events prior to the formal issuance of the quarterly financial
statements.
Investor Relations Contact:
Bernard Girma +1-949-215-7754